Development of an Individualized Immune Prognostic Signature for Clear Cell Renal Cell Carcinoma through the Identification of Differential Immune Genes
Table 2
Clinical features of the low- and high-risk groups in the TCGA cohort.
Clinical parameters
Total
High risk
Low risk
value
530
265
265
Sex
Female
186
91
95
0.7848238
Male
344
174
170
Age
≤65
348
176
172
0.7837531
>65
182
89
93
Grade
G1 + G2
241
97
144
0.1655402
G3 + G4
281
164
117
Gx or unknown
8
4
4
Stage
Stage I + II
322
138
184
9.18E − 05
Stage III + IV
205
124
81
Unknown
3
3
0
T
T1
271
115
156
0.0005092
T2 + 3 + 4
259
150
109
M
M0
420
195
225
0.0048623
M1
78
51
27
Mx or unknown
32
19
13
N
N0
239
119
120
0.0088965
N1
16
14
2
Nx
275
132
143
T, tumor; M, metastasis; N, lymph nodes. values were obtained by Fisher’s test.
